ClinicalTrials.gg
RecruitingNCT06113731Updated Nov 8, 2023

A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

A Phase 2 interventional study of COVID-19 mRNA Vaccine (ZSVG-02-O) and COVID-19 mRNA Vaccine (ZSVG-02-O) in SARS-CoV-2 Infection, sponsored by CNBG-Virogin Biotech (Shanghai) Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by CNBG-Virogin Biotech (Shanghai) Ltd. · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jul 2023, registered Oct 2023).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
980
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.

Planned enrollment
2nd of 12
980 · median 157
Started
2023
with 2 others
Phase 2
3 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
2 of 12
CNBG-Virogin Biotech (Shanghai) Ltd.

Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2023, is one of 3 in phase 2, and was the 9th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About mRNA COVID-19 Vaccine

mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA COVID-19 Vaccine in COVID-19, or all of them as a file.
02

Study summary

To evaluate the immunogenicity and safety of a COVID-19 mRNA vaccine (ZSVG-02-O) in a healthy population aged 18 years and older.

Read the detailed description

This study uses a randomized, blinded and controlled design, with age stratification of 18-59 years and ≥60 years , including the test vaccine at different doses (30 μg and 60 μg) and an active control vaccine.

A total of 980 subjects will be enrolled in this study. 490 subjects aged 18-59 years will be randomly assigned to cohort A1 (test vaccine dose 1), A2 (test vaccine dose 2) and A3 (control vaccine) for the 2-dose regimen (0,28-day) and to cohort A4 (test vaccine dose 1), A5 (test vaccine dose 2) and A6 (active control) for the 1-dose regimen in a ratio of 3:3:1:3:3:1. Another 490 subjects aged 60 years or older will be randomized to cohort B1 (test vaccine dose 1), B2 (test vaccine dose 2) and B3 (active control) for the 2-dose regimen (0,28-day), and cohort B4 (test vaccine dose 1), B5 (test vaccine dose 2) and B6 (control vaccine) for the 1-dose regimen in a ratio of 3:3:1:3:3:1.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects aged ≥18 years of age;
  2. Subjects who are in good physical condition as judged by the investigator based on medical history, physical examination and clinical laboratory tests;
  3. Subjects who have not been previously vaccinated with a Covid-19 vaccine or who have received the last dose (total dose ≤ 3 doses) of a Covid-19 vaccine at least 6 months ago;
  4. Subjects who have not been previously infected with Covid-19, or whose nucleic acid or antigen test has turned negative for more than 3 months after previous Covid-19 infection;
  5. Subjects are able to understand the study procedures, have provide written , and are able to comply with the requirements of the clinical study protocol.

Exclusion criteria

Exclusion criteria

  1. Axillary temperature ≥37.3°C;
  2. Positive polymerase chain reaction (PCR) test results within the last 48 hours;
  3. Women of with a positive urine pregnancy test result, or who are pregnant or breastfeeding, or who have not used effective within 2 weeks prior to enrolment, or women and men who plan to have children within 12 months after full immunisation;
  4. History of epilepsy, convulsions or seizures, psychosis or family history of psychosis;
  5. Have a history of severe allergy to any medication or vaccination (e.g. acute allergic reaction, urticaria, skin eczema, dyspnoea, angioneurotic oedema, or abdominal pain) or allergy to known components of a Covid-19 vaccine;
  6. Have a history of hospital-diagnosed thrombocytopenia or other coagulation disorders;
  7. Have a history of hospital-diagnosed known immunological impairment or hypofunction;
  8. Subjects who have received whole blood, plasma or immunoglobulin therapy within 3 months;
  9. Known or suspected concomitant serious diseases, including: respiratory diseases, acute infections or active chronic diseases, liver and kidney diseases, severe diabetes, malignant tumours, infectious or allergic skin diseases, and infection (with test report);
  10. Have serious cardiovascular diseases, cardiopulmonary failure, hypertension that cannot be controlled by medication (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg on physical examination);
  11. Received within 1 month prior to vaccination or other vaccines within 14 days prior to vaccination;
  12. Participation in a clinical trial of another drug within 3 months prior to the first dose of vaccine or planning to participate in a clinical trial of another drug during the study period;
  13. Any other conditions that the investigator considers inappropriate for participation in this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
980 participants (estimated)

Study arms

  • Experimental
    Test vaccine dose 1, 2 dose

    Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)

  • Experimental
    Test vaccine dose 2, 2 dose

    Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)

  • Active comparator
    Active Comparator, 2 dose

    Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated

  • Experimental
    Test vaccine dose 1, 1 dose

    Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)

  • Experimental
    Test vaccine dose 2, 1 dose

    Biological: COVID-19 mRNA Vaccine (ZSVG-02-O)

  • Active comparator
    Active Comparator,1 dose

    Biological: COVID-19 Vaccine (Vero Cell) ,Inactivated

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric mean titre (GMT) and 4-fold increasing rate of neutralizing antibodies (NAbs) against SARS-CoV-2 on 28 days after full vaccination

    Geometric mean titre (GMT) and 4-fold increasing rate of neutralizing antibodies (NAbs) against SARS-CoV-2 on 28 days after full vaccination

    Time frame: 28 days after full immunisation

Secondary outcomes

  1. GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 14 days after full vaccination

    GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 14 days after full vaccination

    Time frame: 14 days after full immunisation

  2. GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 7 days after the first immunisation

    GMT and 4-fold increasing rate of NAbs against SARS-CoV-2 on 7 days after the first immunisation

    Time frame: 7 days after the first immunisation

  3. Proportion of NAbs against SARS-CoV-2 titres≥1:16, ≥1:32 and ≥1:64 on 14 and 28 days after full immunisation

    Proportion of NAbs against SARS-CoV-2 titres≥1:16, ≥1:32 and ≥1:64 on 14 and 28 days after full immunisation

    Time frame: 14 days and 28 days after full immunisation

  4. GMT, 4-fold increasing rate and ratio of antibody titres ≥1:16, ≥1:32 and ≥1:64 for NAbs against SARS-CoV-2 on 90 and 180 days after full immunisation

    GMT, 4-fold increasing rate and ratio of antibody titres ≥1:16, ≥1:32 and ≥1:64 for NAbs against SARS-CoV-2 on 90 and 180 days after full immunisation

    Time frame: 90 days and 180 days after full immunisation

  5. Incidence and severity of adverse event (AE) within 30 minutes of each dose of vaccination

    Incidence and severity of AE within 30 minutes of each dose of vaccination

    Time frame: From the start of each immunisation until 30 minutes after each immunisation

  6. Incidence and severity of adverse reactions/events 0-14 days after each dose of vaccination

    Incidence and severity of adverse reactions/events 0-14 days after each dose of vaccination

    Time frame: Day 0~Day 14 after each immunisation

  7. Incidence and severity of adverse reactions/events 15-28 days after each dose of vaccination

    Incidence and severity of adverse reactions/events 15-28 days after each dose of vaccination

    Time frame: Day 15~Day 28 after each immunisation

  8. Incidence of serious adverse event (SAE) from the start of vaccination to 12 months after full vaccination

    Incidence of SAE from the start of vaccination to 12 months after full vaccination

    Time frame: From the first dose of immunisation to 12 months after full immunisation

Other outcomes

  1. Changes in cytokine levels in Th1/Th2 cells induced by S protein

    Cytokine \[IFN-γ, interleukin(IL)-4, IL-2\] levels in Th1/Th2 cells changed from pre-dose to 28 days after the full immunisation

    Time frame: From before the first dose of immunisation to 28 days after full immunisation

  2. Cross-neutralisation against different SARS-CoV-2 variants

    The cross-neutralization effect of the mRNA vaccine (Omicron strain) against different SARS-CoV-2 variants (ancestral strain, Omicron strain and main circulating strain)

    Time frame: From the first dose of immunisation to 28 days after full immunisation

07

Study locations

2 of 2 sites recruiting
  • Dengfeng Centre for Disease Control and Prevention and Control
    Dengfeng, Henan, China
    Recruiting
  • Henan Provincial Centre for Disease Control and Prevention
    Zhengzhou, Henan, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2023, 3 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 2, 2023
StartActual
Jul 10, 2023
Primary completionActual
Oct 30, 2023
CompletionEst.
Oct 2024
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06113731
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Jul 10, 2023
Primary completion
Oct 30, 2023
Completion
Oct 2024 (estimated)
Last update
Nov 8, 2023

Study contacts

Yanxia Wang
Contact
wangyanxia99@163.com
+86-13613816598
Yunkai Yang
study chair · China National Biotec Group Company Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion